By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
Merrimack (MACK) Announces Completion Of Enrollment In Phase II CARRIE Study Of MM-141; Data Expected In First Half Of 2018 6/19/2017 6:24:26 AM
Merrimack (MACK) Announces Expansion Of Senior Management Team With Appointment Of Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources 6/8/2017 7:02:15 AM
Merrimack (MACK) CFO To Step Down, Effective June 9 5/26/2017 6:11:17 AM
Merrimack (MACK) Reports First Quarter 2017 Financial Results 5/10/2017 11:29:37 AM
Merrimack (MACK) Announces Timing Of First Quarter 2017 Investor Conference Call 5/3/2017 10:16:33 AM
BioSurplus To Auction Lab Assets From Merrimack (MACK) In Cambridge, Mass. 4/26/2017 9:55:33 AM
Merrimack (MACK) Appoints Daryl Drummond, Ph.D. As Head Of Research 4/17/2017 6:56:49 AM
Merrimack (MACK) Declares $140M Special Dividend In Connection With Recently Completed Asset Sale 4/6/2017 8:30:32 AM
Merrimack (MACK) Launches As New, Refocused Research & Clinical Development Company With Resources To Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 And MM-310 4/3/2017 12:20:22 PM
Ipsen (IPN.PA) Completes Acquisition Of ONIVYDE (Irinotecan Liposome Injection) And Additional Oncology Assets From Merrimack (MACK) 4/3/2017 11:27:41 AM